Clinical trial

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

NCT06668103

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention ABSK043 in combination with Firmonertinib Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-11-25

PhasePHASE2

Conditions

Non-Small Cell Lung Cancer With EGFR Mutationunresolved

Interventions

ABSK043 in combination with FirmonertinibDRUG

Sponsors & collaborators

Abbisko Therapeutics Co, Ltdlead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1 WuhanHubei, China1 ChangchunJilin, China1 HefeiAnhui, China1 HarbinHeilongjiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06668103 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.